EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

T2‐Fluid‐attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone

Inés Esparragosa Vazquez iD, Mané Ndiaye, Anna Luisa Di Stefano, Nadia Younan, Delphine Larrieu-Ciron, Antoine Seyve, Thiébaud Picart, David Meyronet, Claire Boutet, François Vassal, Catherine Carpentier, Dominique Figarella-Branger and 5 more

European Journal of Neurology · 2023

DOI: 10.1111/ene.15873 ↗

At a glance

Journal article in European Journal of Neurology, 2023. Written by Inés Esparragosa Vazquez and 16 co-authors. Institution: Neuro-Oncology Department, Hospices Civils of Lyon, Lyon, France. Major MEDLINE topics: Oligodendroglioma, Brain Neoplasms. Cited 7 times so far (Crossref); 9 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: European Academy of Neurology.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Pseudoprogression in gliomas has been extensively described after radiotherapy with or without chemotherapy, but not after chemotherapy alone. Here we describe the occurrence of pseudoprogression in patients with anaplastic oligodendrogliomas treated with postoperative procarbazine, lomustine and vincristine (PCV) chemotherapy alone.

Methods

We retrospectively reviewed the medical and radiological files of patients with 1p/19q codeleted, IDH‐mutant anaplastic oligodendrogliomas treated with PCV chemotherapy alone who presented magnetic resonance imaging (MRI) modifications suggestive of tumour progression and in whom the final diagnosis was a pseudoprogression.

Results

We identified six patients. All patients underwent a surgical resection and were treated with PCV chemotherapy without radiotherapy. After a median of 11 months following the initiation of chemotherapy (range: 3–49 months), the patients developed asymptomatic white matter MRI modifications around the surgical cavity leading to the suspicion of a tumour progression. These modifications appeared as hyperintense on T2‐fluid‐attenuated inversion recovery (FLAIR) sequence, hypointense on T1 sequence, and lacked mass effect (0/6), contrast enhancement (0/6), restriction on diffusion‐weighted imaging (0/4), relative cerebral blood volume (rCBV) increase on perfusion MRI (0/4), and hypermetabolism on 18 F‐fluoro‐L‐dopa positron emission tomography ( 18 F‐DOPA PET) scan (0/3). One patient underwent a surgical resection demonstrating no tumour recurrence; the five other patients were considered as having post‐therapeutic modifications based on imaging characteristics. After a median follow‐up of 4 years all patients were progression‐free.

Conclusions

Anaplastic oligodendroglioma patients treated with postoperative PCV chemotherapy alone occasionally develop T2/FLAIR hyperintensities around the surgical cavity that can wrongly suggest tumour progression. Multimodal imaging and close follow‐up should be considered in this situation.

Subjects

MeSH terms (MEDLINE)

OligodendrogliomaBrain NeoplasmsHumansLomustineVincristineProcarbazineRetrospective StudiesAntineoplastic Combined Chemotherapy ProtocolsNeoplasm Recurrence, LocalMagnetic Resonance Imaging

Author keywords

PCV chemotherapyanaplastic oligodendrogliomapseudoprogressionradiotherapy

Substances

LomustineVincristineProcarbazine

Authors and institutions

  • Neuro-Oncology Department, Hospices Civils of Lyon, Lyon, France.
  • Neuro-Oncology Department, Centre Georges François Leclerc, Dijon, France.
  • Neuro-Oncology Department, Hôpital Foch, Suresnes, France.
  • Neuro-Oncology Department, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
  • Neuro-Surgery Department, Hospices Civils of Lyon, Lyon, France.
  • Neuropathology Department, Hospices Civils of Lyon, Lyon, France.

ORCID profiles: Inés Esparragosa Vazquez

Funding

  • European Academy of Neurology

Cite

APA

Esparragosa Vazquez, I., Ndiaye, M., Di Stefano, A. L., Younan, N., Larrieu-Ciron, D., Seyve, A., Picart, T., Meyronet, D., Boutet, C., Vassal, F., Carpentier, C., Figarella-Branger, D., Dehais, C., Forest, F., Rivoirard, R., Ducray, F., & POLA network (2023). T2‐Fluid‐attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone. European Journal of Neurology. https://doi.org/10.1111/ene.15873

Vancouver

Esparragosa Vazquez I, Ndiaye M, Di Stefano AL, Younan N, Larrieu-Ciron D, Seyve A, et al. T2‐Fluid‐attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone. European Journal of Neurology. 2023. doi:10.1111/ene.15873

BibTeX
@article{EsparragosaVazquez2023,
  author = {Esparragosa Vazquez, Inés and Ndiaye, Mané and Di Stefano, Anna Luisa and Younan, Nadia and Larrieu-Ciron, Delphine and Seyve, Antoine and Picart, Thiébaud and Meyronet, David and Boutet, Claire and Vassal, François and Carpentier, Catherine and Figarella-Branger, Dominique and Dehais, Caroline and Forest, Fabien and Rivoirard, Romain and Ducray, François and POLA network, POLA network},
  title = {T2‐Fluid‐attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone},
  journal = {European Journal of Neurology},
  year = {2023},
  doi = {10.1111/ene.15873}
}
Start for free →